MedTrace Logo

Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage

NCT01878136 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2015-11-11

No results posted yet for this study

Summary

This study will evaluate the hypothesis that the administration of intraventricular tPA reduces the rates of cerebral vasospasm and ventriculoperitoneal shunt-dependent hydrocephalus in patients with aneurysmal subarachnoid hemorrhage.

Conditions

  • Subarachnoid Hemorrhage
  • Cerebral Vasospasm
  • Cerebral Aneurysm
  • Hydrocephalus

Interventions

DRUG

Tissue Plasminogen Activator

Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)

Sponsors & Collaborators

  • Rush University Medical Center

    lead OTHER

Principal Investigators

  • Stephan Munich, MD · Rush University Medical Center, Department of Neurosurgery

  • Roham Moftakhar, MD · Rush University Medical Center, Department of Neurosurgery

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01878136 on ClinicalTrials.gov